Hospital Universitario de Navarra
Hospital Universitario de Navarra
Pamplona, Spain30 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 3 | 2026-10-09 | NCT07284849 | |
| An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Epileptic Syndromes, Lennox-Gastaut syndrome, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, epilepsy, hereditary disease, nervous system disorder, visual epilepsy | Recruiting | Phase 3 | 2026-10-09 | NCT05066217 | |
| Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-10-07 | NCT07195695 | |
| Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-10-07 | NCT05512364 | |
| The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C) | Arterial Occlusive Diseases, Ventricular Dysfunction, Ventricular Dysfunction, Left, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, heart failure, myocardial ischemia, systolic heart failure, vascular disorder | Recruiting | Not applicable | 2026-10-06 | NCT05427370 | |
| The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis | bronchial disorder, bronchiectasis, respiratory system disorder | Recruiting | Phase 3 | 2026-10-01 | NCT06872892 | |
| A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia | Mixed Dyslipidemia; Primary Hypercholesterolemiia | Active, not recruiting | Not stated | 2026-09-30 | NCT06686615 | |
| DEBSCAN-IVL. Drug Eluting Balloon or Drug Eluting Stent to Treat CAlcified Nodules After IntraVascular Lithotripsy. | Arterial Occlusive Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Recruiting | Not applicable | 2026-09-30 | NCT06657833 | |
| Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia | Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, metabolic disease | Active, not recruiting | Not stated | 2026-09-30 | NCT04579367 | |
| DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy | Extrapulmonary Neuroendocrine Cancer (epNEC) | Recruiting | Phase 3 | 2026-09-29 | NCT07544654 | |
| MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-09-18 | NCT06534437 | |
| ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, injury, neoplasm, radiation injury, skin disorder | Recruiting | Not applicable | 2026-09-17 | NCT04889924 | |
| A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | gastroesophageal junction adenocarcinoma | Recruiting | Phase 3 | 2026-09-14 | NCT07043400 | |
| LONG NAGOMI™ PMCF STUDY | Arterial Occlusive Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Recruiting | Not stated | 2026-09-11 | NCT07399002 | |
| Ultrathin Strut Sirolimus-eluting Stent With Bioabsorbable Polymer in Patients Receiving Chronic Oral Anticoagulation | Arterial Occlusive Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Recruiting | Not stated | 2026-08-06 | NCT06863155 | |
| A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal disorder, esophageal squamous cell carcinoma, neoplasm, squamous cell carcinoma, squamous cell neoplasm | Recruiting | Phase 3 | 2026-08-04 | NCT06644781 | |
| A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | Adnexal Diseases, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, acinar cell carcinoma, adenocarcinoma, carcinoma, central nervous system malformation, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, fallopian tube cancer, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, hereditary disease, hereditary sensory and autonomic neuropathy, inherited neurodegenerative disorder, intestinal disorder, malignant endocrine neoplasm, metastatic malignant neoplasm, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, ovarian cancer, ovarian disorder, pancreatic ductal adenocarcinoma, peripheral nervous system disorder, polyneuropathy, primary peritoneal carcinoma, rectal disorder, uterine disorder | Recruiting | Phase 1 / Phase 2 | 2026-07-30 | NCT04657068 | |
| Multicomponent Exercise to Prevent Hospitalization-Associated Disability | Clinical Deterioration, Disease Attributes, Disease Progression, Pathologic Processes, Pathological Conditions, Signs and Symptoms | Recruiting | Not applicable | 2026-07-16 | NCT07707310 | |
| Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Trial | Arterial Occlusive Diseases, Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, ST-elevation myocardial infarction, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, vascular disorder | Active, not recruiting | Not applicable | 2026-07-15 | NCT05599061 | |
| A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy | multifocal motor neuropathy | Active, not recruiting | Not stated | 2026-05-29 | NCT05988073 | |
| Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome | Frailty, Infarction, Iron Deficiencies, Necrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute coronary syndrome, cardiovascular disorder, heart disorder, iron metabolism disease, ischemic disease, metabolic disease, myocardial infarction, myocardial ischemia, vascular disorder | Recruiting | Phase 4 | 2026-03-24 | NCT07476859 | |
| Parenteral Antiplatelet Agents in Real-world Spanish PCI Patients | acute coronary syndrome, cardiovascular disorder, heart disorder, myocardial ischemia, vascular disorder | Active, not recruiting | Not stated | 2026-02-10 | NCT05193019 | |
| Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress | Arrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, heart disorder, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Phase 4 | 2026-01-12 | NCT03968393 | |
| Evaluation of the Viability and Safety of Early Discharge Protocol After TAVI Implantation | Ventricular Outflow Obstruction, aortic valve disorder, aortic valve stenosis, cardiovascular disorder, heart disorder, heart valve disorder | Active, not recruiting | Not stated | 2025-12-19 | NCT05758909 | |
| Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2025-11-19 | NCT04565054 |